Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bachelot

Showing results (1-10 of 254) with videos related to

Pageof 26
Sort By:
Targeted Oncology|July 16, 2013
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancerVéronique Diéras, Thomas Bachelot
The Lancet. Oncology|January 27, 2022
Medical treatment for active breast cancer brain metastasesCaroline Bailleux, Thomas Bachelot
The Lancet. Oncology|April 23, 2013
Targeted treatments for breast cancer: a step forwardThomas Bachelot, Olivier Tredan
Current Opinion in Oncology|September 5, 2020
Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancerLauriane Eberst, Caroline Bailleux, Thomas Bachelot
British Journal of Cancer|November 30, 2020
Treatment strategies for breast cancer brain metastasesCaroline Bailleux, Lauriane Eberst, Thomas Bachelot
The Lancet. Oncology|May 9, 2016
PI3K targeting in breast cancer: the end of the beginning?Thomas Bachelot, Mario Campone, Olivier Tredan
Frontiers in Oncology|January 25, 2024
Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literatureAxel de Bernardi, Thomas Bachelot, Louis Larrouquère
Bulletin Du Cancer|March 1, 2003
[Clinical development of anti-angiogenic agents in 2002]Thomas Bachelot, Emmanuel Jouanneau, Jean-Yves Blay
La Revue Du Praticien|June 6, 2008
[Adjuvant chemotherapy for breast cancer and targeted therapies]Armelle Dufresne, Thomas Bachelot, Jean-Yves Blay
Bulletin Du Cancer|December 31, 2021
Thomas Bachelot, Caroline Bailleux, Amélie Darlix, et al.
Pageof 26

Showing results (1-10 of 254) with videos related to

Sort By:
Pageof 26
Targeted Oncology|July 16, 2013
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancerVéronique Diéras, Thomas Bachelot
The Lancet. Oncology|January 27, 2022
Medical treatment for active breast cancer brain metastasesCaroline Bailleux, Thomas Bachelot
The Lancet. Oncology|April 23, 2013
Targeted treatments for breast cancer: a step forwardThomas Bachelot, Olivier Tredan
Current Opinion in Oncology|September 5, 2020
Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancerLauriane Eberst, Caroline Bailleux, Thomas Bachelot
British Journal of Cancer|November 30, 2020
Treatment strategies for breast cancer brain metastasesCaroline Bailleux, Lauriane Eberst, Thomas Bachelot
The Lancet. Oncology|May 9, 2016
PI3K targeting in breast cancer: the end of the beginning?Thomas Bachelot, Mario Campone, Olivier Tredan
Frontiers in Oncology|January 25, 2024
Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literatureAxel de Bernardi, Thomas Bachelot, Louis Larrouquère
Bulletin Du Cancer|March 1, 2003
[Clinical development of anti-angiogenic agents in 2002]Thomas Bachelot, Emmanuel Jouanneau, Jean-Yves Blay
La Revue Du Praticien|June 6, 2008
[Adjuvant chemotherapy for breast cancer and targeted therapies]Armelle Dufresne, Thomas Bachelot, Jean-Yves Blay
Bulletin Du Cancer|December 31, 2021
Thomas Bachelot, Caroline Bailleux, Amélie Darlix, et al.
Pageof 26